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Abstract
Background: Despite large-scale vaccination programmes, pertussis has remained endemic in all European countries and
has been on the rise in many countries in the last decade. One of the reasons that have been discussed for the failure of
vaccination to eliminate the disease is continued circulation of the pathogen Bordetella pertussis by mostly asymptomatic
and mild infections in adolescents and adults. To understand the impact of asymptomatic and undiagnosed infection on the
transmission dynamics of pertussis we analysed serological data from five European countries in combination with
information about social contact patterns from five of those countries to estimate incidence and reproduction numbers.
Methods and Findings: We compared two different methods for estimating incidence from individual data on IgG pertussis
toxin (PT) titres. One method combines the cross-sectional surveys of titres with longitudinal information about the
distribution of amplitude and decay rate of titres in a back-calculation approach. The second method uses age-dependent
contact matrices and cross-sectional surveys of IgG PT titres to estimate a next generation matrix for pertussis transmission
among age groups. The next generation approach allows for computation of basic reproduction numbers for five European
countries. Our main findings are that the seroincidence of infections as estimated with the first method in all countries lies
between 1% and 6% per annum with a peak in the adolescent age groups and a second lower peak in young adults. The
incidence of infections as estimated by the second method lies slightly lower with ranges between 1% and 4% per annum.
There is a remarkably good agreement of the results obtained with the two methods. The basic reproduction numbers are
similar across countries at around 5.5.
Conclusions: Vaccination with currently used vaccines cannot prevent continued circulation and reinfection with pertussis,
but has shifted the bulk of infections to adolescents and adults. If a vaccine conferring lifelong protection against clinical
and subclinical infection were available pertussis could be eliminated. Currently, continuing circulation of the pathogen at a
subclinical level provides a refuge for the pathogen in which it can evolve and adjust to infect vaccinated populations.
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There has been a long-standing discussion in the public health
community about how mass vaccination impacts the circulation
of B. pertussis in a population and how it reduces transmission
[1,2]. Over the last decade pertussis has reemerged in many
countries where large-scale vaccination programmes have been
in place since the middle of the last century. After a period
during which infections with the bacterial pathogen B. pertussis
seemed to be under control, pertussis incidence is now reportedly
rising in many Western countries, even those with stable and
high vaccination coverage. Several reasons have been put
forward to explain these trends: a surveillance artifact due to
the introduction of new diagnostic methods or a true
epidemiological observation representing, for example, waning
vaccine-induced protection. With respect to the latter explana-
tion it is now known that subclinical infections in adolescent and
adult populations may play a major role in the persistent
circulation of B. pertussis in highly vaccinated populations [3].
Immunity after natural infection and vaccine-induced immunity
both wane after some years and reinfection of previously infected
or of vaccinated individuals have both been observed [4]. Prior
immunization, as well as older age, usually results in a milder
clinical presentation of the infection, such that pertussis
infections in adults are often not recognized or diagnosed.
Nevertheless, asymptomatically infected persons can be a source
of new infection and can pose a threat to children who are too
young to be vaccinated, and are therefore susceptible to
potentially severe pertussis infection [5].
What is the most effective vaccination strategy to protect those
who might suffer the most severe complications following infection
with B. pertussis? Several mathematical modelling studies have been
conductedtoassesstheeffectiveness ofvarious vaccination strategies
on pertussis incidence [6–9]. All of those studies suffered from a lack
of quantitative input information about the impact of subclinical
infections on the transmission dynamics of B. pertussis and the
difficulty in interpreting pertussis notification data. Nevertheless,
following recommendations from such modelling analyses, adoles-
cent or adult booster vaccination has been introduced in several
countries. The so-called ‘cocooning strategy’ is also under
discussion, an approach that consists of vaccinating household
members of newborn infants [7]. An accurate assessment of the
potential effectiveness of these vaccination strategies rests on a firm
knowledge of the incidence of infection in older age groups and on
quantitative estimates of the transmission potential of infected
persons in these groups. Notification data are a weak source of
information in that respect, because of the mostly asymptomatic/
mildly symptomatic nature of pertussis in these older-age groups
[10,11]. Therefore other methods to estimate pertussis incidence
have been developed using seroepidemiological approaches [12].
These approaches have used high titres of anti-pertussis toxin as a
marker of recent infection [13]. A quantitative description of the
time course of serum antibody titres following infection (serocon-
version) allows translation of the titres in a cross-sectional sample
into times since infection. The statistical methods first developed to
analyse such data have since been extended and applied to other
pathogens [14,15]. For pertussis these studies have produced
estimates in line with other epidemiological studies [16–18].
In a parallel development, the importance of a sound knowledge
of contact patterns leading to infection was recognized in the
context of mathematical modelling of infections spread by close
contact [19,20]. Therefore, social contact data were collected in
several European countries in the years 2005/2006, enabling age-
dependent mixing patterns to be described for eight European
countries [21].
In this article, we bring these two branches of research together
by combining the statistical methods for estimating seroincidence
and the methods for estimating reproduction numbers of
serological data and contact mixing matrices. We apply these
methods to previously published standardized pertussis serological
data from five European countries (Finland, Germany, Italy, The
Netherlands, and United Kingdom) as collected during the mid-
1990s prior to the introduction of adolescent booster doses [13].
We also use age-dependent contact data from the same countries,
as collected during the POLYMOD project (a European Union
funded project on ‘‘Improving Public Health Policy in Europe
through the Modelling and Economic Evaluation of Interventions
for the Control of Infectious Diseases’’) [21]. We show that two
different statistical methods result in comparable estimates for the
incidence of pertussis infections in those countries and report on
estimates for the basic reproduction number for pertussis infection.
Methods
Serological Data, Immunization Scheme, and Coverages
During the European Sero Epidemiology Network (ESEN)
project serological data were collected in seven European
countries for a number of infectious diseases, including pertussis.
Standardization methods were developed for comparison of
antibody titres among the countries such that the serological
status of different populations could be compared. For pertussis
the measurement of IgG pertussis toxin (PT) antibodies was
standardized [22] and standardized measurements of the distri-
bution of IgG PT titres were available for representative
population samples from six different countries (Finland, Ger-
many, Italy, The Netherlands, England and Wales, and France)
across the entire age range. We decided to use the standardized
IgG PT titres from the first part of the project, because the
standardization was well established, the results are published, and
at the time of the serosurveys undertaken in the mid-1990s,
pertussis booster vaccination was not yet implemented in the
majority of countries (Table 1). We do not report on the results for
France, because for France there were no social contact data
available.
We utilised the previously published ESEN pertussis dataset
[13] with individual records of IgG PT titre value by age, sex, and
country. As there seemed to be no difference between males and
females in the distribution of titre values, we did not further
distinguish by gender. In addition to the serological data, we used
information about the age distribution of the population in the
different countries obtained from national population censuses as
in [21].
Social Contact Data
As described in more detail in [21], cross-sectional surveys of
contact patterns were conducted in Belgium (BE), Germany (DE),
Finland (FI), Great Britain excluding Northern Ireland (GB), Italy
(IT), Luxembourg (LU), The Netherlands (NL), and Poland (PL).
In all countries samples representative for the general population
were aimed for with an oversampling of children of 0–5 y of age.
Data collection was organized for each country separately and
slightly different methodologies were employed: in six countries
random digit phone dialling was used for the recruitment of
participants, in two countries recruitment was performed face-to-
face (random walking route) either as a separate study (Poland) or
as a part of a multitheme survey (Germany). Participants in The
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The surveys were performed between May 2005 and September
2006. In The Netherlands the survey was part of a larger
serological study and the sample provided for this analysis was
smaller than for other countries. Participants received a self-
administered questionnaire in the form of a diary and were asked
to fill in each contact made during the course of one day. A
contact was defined either as a two-way conversation in close
proximity or as a conversation including physical contact like
shaking hands or kissing. Among others, information about the age
or age range of the contact person was collected. Since the study
covered all age groups, two or three different versions of the
questionnaire were used: in all countries but Germany, a
questionnaire for children (0–14 y), adolescents (15–18 y), and
adults (19+ y); in Germany only two versions of the questionnaire
were used: for children or young adolescents (0–14 y) and for older
adolescents or adults (15+ y). Questionnaires for young children
were filled in by parents or guardians. Informed consent was
obtained prior to the distribution of the questionnaire. From these
questionnaires, data matrices can be derived that describe the
frequencies of contacts between different age groups of a
population. For the purposes here, we used contact matrices that
describe the frequencies of contacts in populations subdivided into
15 age classes 0–4 y, 5–9 y, 10–14 y, …, 70+ y.
Method for Estimating Incidence
In [12] and [15] a method for estimating incidence from
serological measurements in a population is described. The
method uses information about the serum antibody response to
infection, peak levels, and decay rates of antibody titres, to back-
calculate times since infection in a cross-sectional serum sample.
This method can be simplified by assuming that new infections
occur following a time homogeneous Poisson process. The
marginal distribution of cross-sectional titres can then be described
as a function of the known serum antibody response parameters
and the unknown Poisson rate of infections (seroconversions). For
pertussis, longitudinal data about the kinetics of IgG PT titres after
infection are available from a study reported in [23]. Statistical
models were fitted to these longitudinal data in [4,24]. Both
amplitude and decay rate of titres are highly variable among
individuals, but their distributions can be well described on the
population level. Estimates for these parameters can then be used
to estimate the seroconversion rate for an observed cross-sectional
IgG PT titre distribution. The underlying assumption is that the
population from which the cross-sectional sample is taken is in
endemic equilibrium. Using the parameter estimates obtained in
[4], we estimated a rate parameter for incidence of new infections
per 5-y age group from each of the five cross-sectional datasets
from the ESEN study. In a sensitivity analysis we checked how the
uncertainty of these estimates was related to the sample sizes in
different age groups.
Method for Estimating Basic Reproduction Number from
Survey Data and Serological Data
In [20] a method was introduced to estimate the basic
reproduction number (R0) from an age-mixing matrix in
combination with serological data. As before, the method assumes
that the population is in endemic equilibrium. It then applies the
concept of the next generation matrix [25] to estimate the force of
infection by age in an iterative procedure. In the original model,
an underlying assumption was that infection implies lifelong
immunity. For the purposes of this paper we modified the method
and applied it with a different interpretation. Let S(a) denote the
fraction of seronegative persons by age, and l(a) the age-
dependent rate of seroconversion. Furthermore, we denote by
1/c the time that an individual remains seropositive after
infection. Then the age-dependent fraction of seronegatives can
be described by the differential equation
dS
da
~{l(a)S(a)zc(1{S(a)) ð1Þ
with initial value S(0)~1. We use IgG PT titre values as a proxy
for recent infection rather than a correlate of protection.
For classifying individuals as seronegative or seropositive,
respectively, we used the cumulative density function
P(x)~
ð x
0
C(s,a,b)ds, ð2Þ
where C(s,a,b) denotes the probability density of a Gamma
distribution with shape parameter a and scale parameter b. The
values for a and b were chosen such (a=7.3 and b=11.1) that at a
cut-off value of 94 U/ml the sensitivity and specificity agree with
values found for diagnostic testing by [26]. P(x) is then the
probability that an individual with IgG PT titre x is classified as
seropositive. The uncertainty in estimating the fraction seroposi-
tives per age group was assessed using bootstrapping methods on
the basis of binomial distributions.
The value of the parameter 1/c was estimated at 1.1 y on the
basis of earlier estimates for the decay of antibody titres after
infection. Combining these decay rates with the probability
function in Equation 2 led to an estimate for the distribution of
the time that an individual will be diagnosed as seropositive after
infection. Then, the force of infection l(a) was estimated with a
maximum likelihood procedure that included an iterative process
of determining the next generation matrix (see Text S1). Here the
Table 1. Vaccination schedules at time of serosurveys [13].
Country
Year of
Serosurvey
Primary
Course (mo)
Booster
(mo)
Coverage in Period
1990–1999 (Percent) Vaccine
Finland 1996 3, 4, 5 24 99 Whole cell
Germany 1995 3, 4, 5 12–15 85 Acellular since 1995
Italy 1996 3, 5, 7 No 53 Acellular since 1995
The Netherlands 1995 3, 4, 5 11 97 Whole cell
UK 1996 2, 3, 4 No 92 Whole cell
doi:10.1371/journal.pmed.1000291.t001
Incidence of Pertussis
PLoS Medicine | www.plosmedicine.org 3 June 2010 | Volume 7 | Issue 6 | e1000291mixing between age classes was based on the symmetrized mixing
matrices from the POLYMOD surveys for five countries (Finland,
Germany, Italy, The Netherlands, UK). We did the analysis for
the matrices on the basis of all contacts and the matrices on the
basis of only those contacts that included physical contact. We
compared the goodness of fit for both types of matrices using the
Bayes Information Criterion (BIC). This is a statistical criterion for
model selection based on the likelihood function with a penalty for
the number of free parameters. From the next generation matrix,
estimates for the basic reproduction number could then be
computed as dominant eigenvalues. We conducted sensitivity
analyses to study the impact of the assumptions about a, b, and c
on the estimates for R0 and the force of infection (unpublished
results). Incidence per annum (t=1) was then computed from the
estimated fractions of seronegatives per age group and the force of
infection by age as
I(a)~S(a)(1{exp({l(a)t)) ð3Þ
By embedding the iteration procedure for obtaining the next
generation matrix into a Markov chain Monte Carlo (MCMC)
algorithm we computed uncertainty bounds (95% credible
intervals) around the estimates for R0 and the incidence.
Sensitivity Analysis Using Hypothetical Contact Matrices
To determine how strongly the incidence estimates that are
based on the contact matrices depended on the specific form of the
matrices, we computed estimates on the basis of two hypothetical
contact matrices. One was a contact matrix describing homoge-
neous mixing between all age classes, i.e., all matrix elements were
chosen as equal. The other hypothetical matrix was based on the
matrix of all conversational contacts from the POLYMOD
surveys, where we reduced the impact of assortative mixing within
age classes by multiplication of the diagonal and first subdiagonal
elements by factors 0.2 and 0.5, respectively. The rationale behind
the second choice was that possibly contacts in households, which
are often between parents and their children, might be of more
importance for pertussis transmission than school or work
contacts, which are strongly assortative between age groups.
All analyses were performed with Mathematica 7.0.
Results
Seroincidence of Pertussis in Five European Countries
Estimating incidences on the basis of longitudinal antibody
decay data from The Netherlands and cross-sectional serological
data from five ESEN countries resulted in the incidence estimates
shown in Figure 1. Overall the annual incidence varies between
around 1% in the UK up to around 6% in Italy and Germany.
The distribution over age classes is comparable across countries
with a peak in the adolescent age classes and a less pronounced
peak in younger adults. The uncertainty in these incidence
estimates varies among age groups and countries (compare The
Netherlands with Finland and Italy, for example). These
differences are mainly caused by different numbers of sera in
each category.
Estimates of the Force Of Infection and Basic
Reproduction Number for Five European Countries
Using the estimation method on the basis of the next generation
matrix approach for the five countries for which both serological
and contact data were available, we estimated the fraction per age
class that is seropositive using a diagnostic test with a cut-off of
94 U/ml (Figure 2). Furthermore we estimated the age-dependent
force of infection (Figure 3). Here The Netherlands and the UK
have the lowest overall force of infection, and Italy and Germany
the highest, whereas Finland takes an intermediate position. The
basic reproduction number in an unvaccinated population can be
computed as the dominant eigenvalue from the estimated next-
generation matrices for each of the five countries (Table 2). The
resulting values between 5 and 6 are similar across all five
countries. When conducting the same analysis on the basis of
contact matrices that included only physical contact, the estimates
for the basic reproduction numbers remain virtually unchanged.
The analysis using physical contact matrices does predict a higher
value of the transmission parameter to account for the lower
numbers of contacts available for transmission (unpublished data).
A comparison of goodness of fit of the model with all contacts
versus the model with only physical contacts shows differing
outcomes per country (Table 3). While for Italy, Germany, and the
UK the physical contact matrices give a slightly better fit, in
Finland and The Netherlands the matrices with all contacts
provide a better model.
Comparison of Incidence from Both Estimation Methods
For the second estimation method incidence estimates can be
computed from the age-dependent fraction of seronegatives and
the force of infection. For the incidence computed in that way the
age distribution differs somewhat from the seroincidences as
estimated with the first method (Figure 4). The age distribution is
more pronounced than for the seroincidence estimates with a
strong peak in the adolescent age classes, especially in those
countries with a high overall force of infection. In countries with a
lower force of infection (The Netherlands, UK) the peak seems to
lie in somewhat younger age classes than in the countries with a
higher overall force of infection, maybe reflecting the faster loss of
immunity after vaccination as compared with natural infection in
young children. Overall, incidence estimates obtained with the
second method are lower than those obtained with the first
method.
Hypothetical Contact Matrices
Sensitivity analysis using hypothetical contact matrices shows
that the age distribution in incidence is strongly determined by the
age-dependent mixing patterns. Homogeneous mixing predicts flat
incidence profiles, while mixing with reduced assortative mixing
produces incidence estimates that closely resemble those obtained
by the back-calculation method (unpublished results). Comparing
the goodness of fit of estimates on the basis of those matrices does
not lead to clear conclusions about the optimal contact patterns. It
is reassuring that the estimates of the reproduction number R0 are
robust with respect to the details of the mixing patterns (Table 2).
Discussion
We estimated the incidence of infection with B. pertussis during
the 1990s from serological data for five European countries using
two novel statistical modelling methods. One method uses
information about the decay rate of antibodies against PT to
estimate infection rates from IgG PT levels in cross-sectional sera.
The other method uses information about age-dependent contact
patterns and fractions of seropositive persons by age to derive an
estimate for the force of infection. The two methods both lead to
high incidence levels overall and for all countries, but there is also
a clear difference between the estimates. We found the incidence
levels were between 1% and 6% for all five countries for the first
method and between 1% and 4% for the second method.
Incidence of Pertussis
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country, the basic reproduction numbers were remarkably similar
across countries, and for contact matrices based on all contacts
versus only physical contacts. The incidences estimated here differ
strongly from incidences found in national surveillance systems
[11], clearly illustrating large underreporting rates and differences
between countries in reporting rates.
The two estimation methods are based on very different ideas
and approaches. The first method assumes that infections occur
according to a time homogeneous Poisson process, whose rate can
be estimated from cross-sectional serological data using informa-
tion about amplitude and decay rate of the host immune response.
The latter has to be estimated independently from longitudinal
studies on antibody kinetics after infection. These methods have
also been applied successfully to infections with other pathogens
such as Campylobacter and Salmonella [15]. The method assumes that
existing antibody levels do not confer any protection against
renewed seroconversion, but considers dynamics of antibodies as a
continuous process of antibody boosting and decay. Nothing is
said about the incidence of symptomatic infections. The second
method is based on the notion of a dynamic transmission model,
where transmission is age dependent and mixing among age
groups occurs according to an age mixing matrix. In this method,
the population is subdivided into seropositive and seronegative
individuals and an infection event moves an individual from the
latter to the former. While the definition of seropositive can be
chosen arbitrarily, here we used properties from a diagnostic test
to calibrate the model, meaning that those found seropositive in
the estimation procedure would be diagnosed as seropositive with
this test. In other words, this second method does not consider all
boosting events as infections, but only those that move an
individual from being seronegative to seropositive. Therefore the
Figure 1. Seroincidence of pertussis in five European countries. Maximum likelihood estimates and (likelihood-based) 95% confidence
intervals for the infection incidence as a function of age (5-y age classes).
doi:10.1371/journal.pmed.1000291.g001
Figure 2. Seropositive fraction per age class from serological data using a standard diagnostic test (dots) and fitted model (solid
line). The error bars represent 95% bootstrapping confidence intervals.
doi:10.1371/journal.pmed.1000291.g002
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the first method. Both methods rely on the assumption that the
transmission dynamic process is at equilibrium. While the first
method is more direct and based only on serological data, the
second method considers immunity to infection and provides the
possibility to estimate the force of infection and basic reproduction
numbers.
Both methods showed a peak in incidence in adolescent age
groups, a second lower peak in the young adult age groups, and a
decreasing incidence at older ages. However, there are some
differences between the incidence estimates obtained with the two
methods. The incidence estimates using the contact matrix data
had more pronounced peaks in the adolescent age groups
compared to the incidence estimates that were derived only from
the serological information. Comparing the explanatory power of
using all contacts versus only physical contacts to estimate the
force of infection led to interesting differences between countries.
In countries with lower vaccination coverage and a higher peak
age of transmission, physical contacts provided a slightly better
proxy for describing transmission dynamics. In countries with high
Figure 3. Estimates for the age-dependent force of infection (risk per year of becoming infected) for five European countries. DE,
Germany; FI, Finland; IT, Italy; NL, The Netherlands.
doi:10.1371/journal.pmed.1000291.g003
Table 2. Estimates for the basic reproduction number (R0) based on the matrices for all contacts, only physical contacts, and two
different hypothetical matrices.
Country
R0 All Contacts
Matrix (95% CI)
R0 Physical Contacts
Matrix (95% CI)
R0 Homogeneous
Mixing Matrix (95% CI)
R0 All Contacts Matrix with
Reduced Diagonals (95% CI)
Finland 5.5 (5.44–5.57) 5.5 (5.45–5.60) 5.7 (5.60–5.71) 5.4 (5.38–5.51)
Germany 5.6 (5.51–5.63) 5.5 (5.47–5.59) 5.8 (5.69–5.81) 5.7 (5.59–5.74)
Italy 5.9 (5.82–6.01) 5.9 (5.82–6.01) 5.8 (5.75–5.89) 5.8 (5.75–5.90)
The Netherlands 5.3 (5.26–5.35) 5.4 (5.30–5.42) 5.4 (5.34–5.42) 5.2 (5.18–5.26)
UK 5.4 (5.27–5.40) 5.2 (5.13–5.27) 5.5 (5.39–5.53) 5.3 (5.23–5.37)
Uncertainty estimates obtained by a Markov chain Monte Carlo (MCMC) algorithm (95% credible intervals [CIs]) in brackets.
doi:10.1371/journal.pmed.1000291.t002
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exception of the UK), the matrix with all conversational contacts
provided a better fit. This might indicate that subclinical infections
are transmitted through varying types of contacts, while clinical
and severe infections require closer contact to be transmitted. The
overall observed incidence levels presented here were comparable
to the high titre prevalence estimates seen in the previous ESEN
study [13] and were in line with earlier results based on a true
back-calculation approach [12].
Comparing the performance of the POLYMOD contact
matrices with two hypothetical contact matrices shows that the
overall contacts patterns obtained by the POLYMOD surveys
might not be optimally suited to describe pertussis transmission
dynamics. The reasons for the suboptimal fit could be that
pertussis transmission mainly occurs within households, where the
assortative age mixing is less pronounced, or that duration and
proximity of contacts have to be weighted by their duration,
frequency, or proximity [27]. Possibly, the distribution of contacts
among different settings, like households, schools, and workplace,
has to be taken into account [28]. Our combined approach of
incidence estimation methods opens up the possibility of
investigating which types of contact matrices are best suited to
describe observed seroepidemiological data and might therefore be
able to give valuable hints about the main transmission routes and
settings for specific pathogens.
Our estimates for the basic reproduction number are lower than
those previously published [29]. However, earlier estimates were
based on the assumption that natural infection provides lifelong
protective immunity against future infections. Although the basic
reproduction numbers estimated here apply to unvaccinated
populations, we expect that the reproduction rates in vaccinated
populations are not much different, because vaccination hardly
seems to prevent repeated subclinical infections, even though it
protects against symptomatic infection. The reproduction numbers
were very similar across countries, and the observed small
differences were consistent with the differences in vaccination
schedules and coverages. Italy and Germany had somewhat higher
reproduction numbers than the remaining countries and also
displayed higher incidence estimates.
The values for the basic reproduction number of pertussis
estimated here, lead us to conclude that pertussis is less
transmissible than other childhood infections such as measles
and rubella. Estimates of the R0 for measles are very high at
around 20 [30] or more [31], for rubella the estimates are at
around 7 [32], but both infections have a shorter infectious period
than pertussis [33]. That means that an infected individual with
Table 3. BIC values for model fit with four different contact matrices.
Country
BIC All Contacts
Matrix
BIC Physical
Contacts Matrix
BIC Homogeneous
Mixing Matrix
BIC All Contacts Matrix
with Reduced Diagonals
Finland 295.44 361.13 337.31 331.89
Germany 343.45 343.17 353.34 368.09
Italy 464.79 449.74 351.08 439.82
The Netherlands 402.32 497.69 347.92 345.02
UK 196.21 162.06 186.81 187.14
Two are empirical contact matrices from the POLYMOD study [21] and two are hypothetical contact matrices. The empirical matrices describe all conversational contacts
and only physical contacts, respectively. As hypothetical contact matrices we chose a homogeneous mixing matrix and a matrix on the basis of the all-contacts matrix,
with reduced diagonal and subdiagonal elements. A lower BIC value indicates a better model fit.
doi:10.1371/journal.pmed.1000291.t003
Figure 4. Comparison of incidence estimates from both estimation methods. Dots, seroincidence with error estimates; solid lines, incidence
of infections that test positively with diagnostic tests with 95% credible intervals (shaded).
doi:10.1371/journal.pmed.1000291.g004
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period on average than previously thought, which is promising for
intervention. Waning immunity accounts for the difficulty in
eliminating pertussis. Infected individuals find sufficient numbers
of susceptible individuals around them to keep circulation going.
This implies that elimination of pertussis will only be possible if a
vaccine can be developed that also confers long-lasting protection
against subclinical infections. The continued circulation of B.
pertussis through mild and asymptomatic infections provides
opportunities for the pathogen to evolve into strains that have
increased virulence in unimmunized hosts, and current vaccines
may not provide complete protection against such new evolved
strains [34].
A potential limitation of our study is that contact patterns for
children in the POLYMOD study were assessed by their parents
[21]. Furthermore, respondents only gave information about the
contacts made during a single day, so time trends in contact
patterns cannot be taken into account. Finally, we only used
information about the numbers of contacts and their distribution
across age classes, and did not include information about the
duration of contacts or the frequency of contact with the same
person. We did, however, examine possible differences between all
conversational contact and only physical contact, but did not find
any effect of using only contacts that included some physical
contact on our results. The data on social contacts were collected
around 10 y after the serological data from the ESEN study. We
assumed here that age-dependent contact patterns remained stable
over that time period. Possible empirical support for this
assumption comes from comparing the contact matrix in [20]
with the contact matrices in [21]. There is a good agreement even
if there is a time span of almost 20 y between the respective data
collections.
Another limitation of our study is that vaccination with various
types of pertussis vaccines might result in increases in titres of IgG
PT; in this analysis we did not take the effects of vaccination on
IgG PT titres into account. Although some pertussis vaccines
hardly affect IgG PT titre levels, others can result in a large
increase in IgG PT titre [13]. However, we did not see any
vaccine-induced seroconversions in the longitudinal study (which
included vaccinated and unvaccinated children). At the time the
ESEN serological data were collected, vaccination in all
participating ESEN countries was limited to the first 2 y of life
[13]. Thus vaccination could have interfered with IgG PT levels in
the youngest age group in some countries, and results in this age-
group should be interpreted cautiously. Some high titres attributed
to natural infection may have resulted from vaccination thereby
leading to an overestimation of the incidence in the youngest age
groups. However this would not be the case for older age-groups.
Also, there were differences in the efficacy of the vaccines used in
different countries at that time, which might partly explain
differences in the force of infection in young children. Future
investigation will probe how to translate seroincidence as
estimated here into conclusions about burden of disease or
incidence of notified infections.
Finally, the assumption of an endemic equilibrium that is made
in both methods might not be supported by the data from the
ESEN study. For many countries, an increase in pertussis
incidence began in the 1990s, and epidemic peaks in incidence
have been observed at regular intervals in some countries [35].
However, the ESEN study seems to have been conducted just
before the major increase in incidence began. Also, recent
infections that are characterized by high IgG-PT titres are less
influenced by long term time trends, and therefore the estimation
methods have an intrinsic robustness concerning time trends.
However, as new cross-sectional serological studies are becoming
available, we are planning to extend our methods to also account
for the effects of changes in vaccination schedules and time trends.
It is known that low IgG PT titres are a correlate of
susceptibility for symptomatic pertussis disease [36], but it is not
known what proportion of all transmission events estimated here
actually lead to symptomatic disease and notification. More
clinical information about the relationship between transmission,
infection, and symptoms is necessary to yield quantitative estimates
of underdiagnosis and underreporting of pertussis. We do,
however, conclude that the epidemiology of pertussis is largely
driven by circulation of the pathogen in adolescent and adult
population groups. Other studies have shown that these groups
suffer less frequently from symptomatic infection than young
children [37]. Therefore, in our efforts to prevent serious infection
in young infants, we should take into account that large reservoirs
of infection exist and design ways to protect young infants from
that risk.
The results presented here, which have been obtained using
novel approaches, add to our understanding of the complex
transmission dynamics of pertussis infection. On the basis of
serological data, we provide a picture of the amount of circulation
that is still taking place even in highly vaccinated populations. This
information can be used to assess the amount of underdiagnosis
and underreporting of pertussis infection and disease. In addition,
the novel methods outlined here could be also used to evaluate the
impact of the programmatic changes that have been implemented
in many countries since these serosurveys were undertaken. In
particular the introduction of preschool and adolescent pertussis
boosters and the acceleration of the primary schedule were
introduced to try to directly protect infants from severe disease.
Supporting Information
Text S1 Detailed methods used for estimation of incidence.
Found at: doi:10.1371/journal.pmed.1000291.s001 (0.06 MB
DOC)
Acknowledgments
We thank Michiel van Boven for many stimulating discussions. We thank
Hester de Melker and Sabine de Greeff for critically reading an earlier
version of the paper. This study benefitted greatly by the input of many
participants of the POLYMOD project, and in particular Jacco Wallinga
and John Edmunds.
We thank the ESEN country representatives Daniel Levy-Bruhl,
Stefania Salmaso, Hester de Melker, Rose-Marie Olander, Annedore
Tischer, and Elizabeth Miller for permission to use the pertussis serological
data collected during the first ESEN project.
Author Contributions
ICMJE criteria for authorship read and met: MK PFT RGP. Agree with
the manuscript’s results and conclusions: MK PFT RGP. Designed the
experiments/the study: MK. Analyzed the data: MK PFT. Collected data/
did experiments for the study: RGP. Wrote the first draft of the paper: MK.
Contributed to the writing of the paper: MK PFT RGP.
References
1. Rohani P, Earn DJ, Grenfell BT (2000) Impact of immunisation on pertussis
transmission in England and Wales. Lancet 355: 285–286.
2. Gay NJ, Miller E (2000) Pertussis transmission in England and Wales. Lancet
355: 1553–1554.
Incidence of Pertussis
PLoS Medicine | www.plosmedicine.org 8 June 2010 | Volume 7 | Issue 6 | e10002913. Schellekens J, von Konig CH, Gardner P (2005) Pertussis sources of infection
and routes of transmission in the vaccination era. Pediatr Infect Dis J 24:
S19–24.
4. Versteegh FG, Mertens PL, de Melker HE, Roord JJ, Schellekens JF, et al.
(2005) Age-specific long-term course of IgG antibodies to pertussis toxin after
symptomatic infection with Bordetella pertussis. Epidemiol Infect 133: 737–748.
5. Cortese MM, Baughman AL, Brown K, Srivastava P (2007) A ‘‘new age’’ in
pertussis prevention new opportunities through adult vaccination. Am J Prev
Med 32: 177–185.
6. Hethcote HW (1997) An age-structured model for pertussis transmission. Math
Biosci 145: 89–136.
7. Van Rie A, Hethcote HW (2004) Adolescent and adult pertussis vaccination:
computer simulations of five new strategies. Vaccine 22: 3154–3165.
8. van Boven M, de Melker HE, Schellekens JF, Kretzschmar M (2000) Waning
immunity and sub-clinical infection in an epidemic model: implications for
pertussis in The Netherlands. Math Biosci 164: 161–182.
9. van Boven M, de Melker HE, Schellekens JF, Kretzschmar M (2001) A model
based evaluation of the 1996–7 pertussis epidemic in The Netherlands.
Epidemiol Infect 127: 73–85.
10. Tozzi AE, Pandolfi E, Celentano LP, Massari M, Salmaso S, et al. (2007)
Comparison of pertussis surveillance systems in Europe. Vaccine 25: 291–297.
11. Celentano LP, Massari M, Paramatti D, Salmaso S, Tozzi AE (2005)
Resurgence of pertussis in Europe. Pediatr Infect Dis J 24: 761–765.
12. de Melker HE, Versteegh FG, Schellekens JF, Teunis PF, Kretzschmar M (2006)
The incidence of Bordetella pertussis infections estimated in the population from
a combination of serological surveys. J Infect 53: 106–113.
13. Pebody RG, Gay NJ, Giammanco A, Baron S, Schellekens J, et al. (2005) The
seroepidemiology of Bordetella pertussis infection in Western Europe. Epidemiol
Infect 133: 159–171.
14. Simonsen J, Molbak K, Falkenhorst G, Krogfelt KA, Linneberg A, et al. (2009)
Estimation of incidences of infectious diseases based on antibody measurements.
Stat Med 28: 1882–1895.
15. Simonsen J, Strid MA, Molbak K, Krogfelt KA, Linneberg A, et al. (2008) Sero-
epidemiology as a tool to study the incidence of Salmonella infections in humans.
Epidemiol Infect 136: 895–902.
16. Deville JG, Cherry JD, Christenson PD, Pineda E, Leach CT, et al. (1995)
Frequency of unrecognized Bordetella pertussis infections in adults. Clin Infect
Dis 21: 639–642.
17. Hodder SL, Cherry JD, Mortimer Jr. EA, Ford AB, Gornbein J, et al. (2000)
Antibody responses to Bordetella pertussis antigens and clinical correlations in
elderly community residents. Clin Infect Dis 31: 7–14.
18. Strebel P, Nordin J, Edwards K, Hunt J, Besser J, et al. (2001) Population-based
incidence of pertussis among adolescents and adults, Minnesota, 1995–1996.
J Infect Dis 183: 1353–1359.
19. Wallinga J, Edmunds WJ, Kretzschmar M (1999) Perspective: human contact
patterns and the spread of airborne infectious diseases. Trends Microbiol 7:
372–377.
20. Wallinga J, Teunis P, Kretzschmar M (2006) Using data on social contacts to
estimate age-specific transmission parameters for respiratory-spread infectious
agents. Am J Epidemiol 164: 936–944.
21. Mossong J, Hens N, Jit M, Beutels P, Auranen K, et al. (2008) Social contacts
and mixing patterns relevant to the spread of infectious diseases. PLoS Med 5:
e74. doi:10.1371/journal.pmed.0050074.
22. Giammanco A, Chiarini A, Maple PA, Andrews N, Pebody R, et al. (2003)
European Sero-Epidemiology Network: standardisation of the assay results for
pertussis. Vaccine 22: 112–120.
23. Versteegh FG, Schellekens JF, Nagelkerke AF, Roord JJ (2002) Laboratory-
confirmed reinfections with Bordetella pertussis. Acta Paediatr 91: 95–97.
24. Teunis PF, van der Heijden OG, de Melker HE, Schellekens JF, Versteegh FG,
et al. (2002) Kinetics of the IgG antibody response to pertussis toxin after
infection with B. pertussis. Epidemiol Infect 129: 479–489.
25. Diekmann O, Heesterbeek JAP (2000) Mathematical epidemiology of infectious
diseases: model building, analysis and interpretation. New York: Wiley.
26. Baughman AL, Bisgard KM, Edwards KM, Guris D, Decker MD, et al. (2004)
Establishment of diagnostic cutoff points for levels of serum antibodies to
pertussis toxin, filamentous hemagglutinin, and fimbriae in adolescents and
adults in the United States. Clin Diagn Lab Immunol 11: 1045–1053.
27. Smieszek T (2009) A mechanistic model of infection: why duration and intensity
of contacts should be included in models of disease spread. Theor Biol Med
Model 6: 25.
28. Kretzschmar M, Mikolajczyk RT (2009) Contact profiles in eight European
countries and implications for modelling the spread of airborne infectious
diseases. PLoS One 4: e5931. doi:10.1371/journal.pone.0005931.
29. Anderson RM, May RM (1991) Infectious disease of humans: dynamics and
control. Oxford: Oxford University Press.
30. Wallinga J, Teunis P, Kretzschmar M (2003) Reconstruction of measles
dynamics in a vaccinated population. Vaccine 21: 2643–2650.
31. van Boven M, Kretzschmar M, Wallinga J, O’Neill P, Wichmann O, et al.
(2010) Estimation of measles vaccine efficacy and critical vaccination coverage in
a highly vaccinated population. J Roy Soc Interface, In press.
32. Edmunds WJ, Gay NJ, Kretzschmar M, Pebody RG, Wachmann H (2000) The
pre-vaccination epidemiology of measles, mumps and rubella in Europe:
implications for modelling studies. Epidemiol Infect 125: 635–650.
33. Richardson M, Elliman D, Maguire H, Simpson J, Nicoll A (2001) Evidence
base of incubation periods, periods of infectiousness and exclusion policies for
the control of communicable diseases in schools and preschools. Pediatr Infect
Dis J 20: 380–391.
34. Mooi FR, van Loo IH, King AJ (2001) Adaptation of Bordetella pertussis to
vaccination: a cause for its reemergence? Emerg Infect Dis 7: 526–528.
35. De Greeff SC, Dekkers AL, Teunis P, Rahamat-Langendoen JC, Mooi FR, et al.
(2009) Seasonal patterns in time series of pertussis. Epidemiol Infect 137:
1388–1395.
36. Storsaeter J, Hallander HO, Gustafsson L, Olin P (2003) Low levels of
antipertussis antibodies plus lack of history of pertussis correlate with
susceptibility after household exposure to Bordetella pertussis. Vaccine 21:
3542–3549.
37. Cherry JD, Grimprel E, Guiso N, Heininger U, Mertsola J (2005) Defining
pertussis epidemiology: clinical, microbiologic and serologic perspectives. Pediatr
Infect Dis J 24: S25–S34.
Incidence of Pertussis
PLoS Medicine | www.plosmedicine.org 9 June 2010 | Volume 7 | Issue 6 | e1000291Editors’ Summary
Background. Pertussis—whooping cough—is a highly
infectious respiratory tract infection caused by Bordetella
pertussis bacteria. The first symptoms of pertussis, which is
spread by sneezing or coughing, are similar to those of a
common cold. Then, after 1–2 weeks, severe outbursts of
coughing develop that end with a characteristic ‘‘whoop.’’
Whooping cough is most common in infants and young
children although adolescents and adults can develop a
mild, often undiagnosed version of the disease. By contrast,
more than half of children who develop pertussis before they
are a year old need hospitalization. Complications of
pertussis include pneumonia, a brain condition called
encephalopathy and, in rare cases, death. Treatment with
antibiotics can shorten the illness and can stop it spreading
to other people. Whooping cough can be prevented by
vaccination—an injection of inactive B. pertussis that
‘‘primes’’ the immune system so that it can deal quickly
and effectively with any subsequent infections. Globally,
more than 80% of children are now vaccinated against
pertussis in the first few months of life.
Why Was This Study Done? Widespread pertussis
vaccination since the 1950s has greatly reduced the
incidence (the number of new cases in a population) of
whooping cough. However, the disease is still present in all
countries and its incidence is increasing again in many
Western countries. One possible reason for vaccination
failing to eliminate whooping cough might be B. pertussis
transmission through mild infections in adolescents and
adults. Because the protection provided by vaccination
wanes over time, people who were vaccinated as infants can
develop mild pertussis as adolescents or adults and
unknowingly infect unvaccinated babies. Currently,
pertussis vaccination involves several injections in the first
few months of life and a preschool booster but some
countries have recently introduced booster doses of
pertussis vaccine for adolescents and adults to try to
improve pertussis control, even though the transmission
dynamics of pertussis in adults and adolescents are poorly
understood. In this study, the researchers estimate the
incidence and basic reproduction number (the expected
number of new cases of a disease caused by an infected
individual) in five European countries to discover more about
the transmission dynamics of pertussis.
What Did the Researchers Do and Find? The researchers
used two new statistical methods to estimate pertussis
incidence from data collected in Finland, Germany, Italy, The
Netherlands, and the UK in the mid-1990s (before the
introduction of adolescent booster doses) on the levels of
antibodies to pertussis in the blood of individuals
(serological data). The first method used information on
the decay rate of pertussis antibodies to estimate infection
rates from these serological data. The annual incidence of
pertussis infections estimated this way ranged from 1% in
the UK to 6% in Italy and Germany with a peak of infections
in adolescents and a second, weaker peak in young adults.
The second method combined the serological data with
information on daily social contacts in the populations of the
same countries collected by the POLYMOD project (a study
designed to strengthen public-health decision making in
Europe). The annual incidence of infections estimated this
way ranged between 1% and 4%, again with a peak of
infection in adolescents. The basic reproduction number of
pertussis infection estimated using the second method was
about 5.5 in all five countries.
What Do These Findings Mean? Although the accuracy
of the estimates reported here may be affected by the
accuracy of the data entered into the calculations, these
findings suggest that the incidences of pertussis in Finland,
Germany, Italy, The Netherlands, and the UK are higher than
the incidences obtained from national surveillance systems.
They provide an indication, therefore, of the scale of
underreporting and/or underdiagnosis of pertussis in these
countries. In addition, they indicate that widespread
vaccination with current vaccine schedules has shifted the
bulk of pertussis infections to adolescents and adults who
rarely develop severe pertussis. Thus, the researchers
suggest, pertussis could be eliminated with moderate
effort if a vaccine, or vaccine schedule, could be developed
that provided life-long protection against pertussis. Finally
and importantly, the two new methods described in this
paper can now be used to find out whether the introduction
of adolescent boosters has actually reduced the incidence of
pertussis.
Additional Information. Please access these Web sites via
the online version of this summary at http://dx.doi.org/10.
1371/journal.pmed.1000291.
N The US Centers for Disease Control and Prevention has a
feature on pertussis (whooping cough) and provides
detailed information on pertussis vaccination (in English
and Spanish)
N KidsHealth, a resource provided by the Nemours Children’s
Health System, has information for parents on pertussis (in
English and Spanish)
N The UK Health Protection Agency provides information
about pertussis and pertussis vaccination
N The National Institute of Public Health and the Environ-
ment (RIVM) of the Netherlands provides information
about pertussis (in Dutch)
N Information about whooping cough is available on the UK
National Health Service Choices website
N Information about the surveillance of pertussis and other
vaccine preventable diseases can be found on the
European surveillance network EUVAC.NET website
N Links to additional resources are provided by MedlinePlus
(in English and Spanish)
N Information on POLYMOD is available
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